Cost-effectiveness of screening for KRAS and BRAF mutations in metastatic colorectal cancer

Ajay Behl, PhD of the HealthPartners Research Foundation in Bloomington, USA and colleagues decided to evaluate the comparative effectiveness of screening for KRAS and BRAF mutations in patients with mCRC. Previous economic analyses of mutation testing have not fully explored the roles of alternative therapies, resection of metastases, and survival for the different types of metastases. The research by Behl and his colleagues was based on a decision analytic framework that forms the basis of a cost-effectiveness analysis of screening for KRAS and BRAF mutations in mCRC in the context of treatment with cetuximab. Read more here.

Study mentioned: Behl AS, et al. Cost-Effectiveness Analysis of Screening for KRAS and BRAF Mutations in Metastatic Colorectal Cancer. JNCI J Natl Cancer Inst. 2012;104(23): 1785-1795.